Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
May 14 2024 - 4:01PM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of seralutinib for the treatment of pulmonary
arterial hypertension (PAH) and pulmonary hypertension associated
with interstitial lung disease (PH-ILD), will present updated
seralutinib TORREY open-label extension data at the American
Thoracic Society 2024 International Conference, which takes place
May 17-22 in San Diego, California.
Details for the oral presentation related to seralutinib, an
inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the
treatment of pulmonary hypertension, are as follows:
Session: A14: Building Lego(Land): Lessons Learned From
Large Scale Clinical Trials In PAH Session Date & Time:
Sunday, May 19th, 9:15 a.m. - 11:15 a.m. PT Talk Title:
Interim Results from the Phase 1B and Phase 2 TORREY Open-label
Extension Study of Seralutinib in Pulmonary Arterial Hypertension
(PAH) Location: San Diego Convention Center, Room 29A-D
(Upper Level) Presenting Author: Olivier Sitbon, MD, PhD
Gossamer also will present additional data on seralutinib via
poster. Details for those posters are as follows:
Poster Board Number: 424 Poster Session: D105
Balboa Park Explorers: Translational Science and Epidemiology in PH
Session Date & Time: Wednesday, May 22nd, 11:00 a.m. –
1:00 p.m. PT Poster Title: TORREY Phase 2 Study of
Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating
Biomarkers of Proliferation, Inflammation, and Fibrosis Improve
with Treatment Location: San Diego Convention Center, Room
25A-C (Upper Level)
Poster Board Number: 318 Poster Session: D109 Now
We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular
Disease Session Date & Time: Wednesday, May 22nd, 11:00
a.m. – 1:00 p.m. PT Poster Title: Cardiac Effort Is Less
Variable Than Six-minute Walk Distance, Correlates with
Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a
Sub-study of the TORREY Phase 2 PAH Trial Location: San
Diego Convention Center, Room 28C-E (Upper Level)
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on the development and commercialization of seralutinib for
the treatment of pulmonary hypertension. Its goal is to be an
industry leader in, and to enhance the lives of patients living
with, pulmonary hypertension.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514616477/en/
For Investors and Media: Bryan Giraudo, Chief Operating
Officer and Chief Financial Officer Gossamer Bio Investor Relations
ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Aug 2023 to Aug 2024